Tonix Zeroes In On Fatigue As Go-Forward Endpoint In Long COVID

05 Sep 2023

The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.

Tonix is developing the drug TNX-102 SL in long COVID • Source: Shutterstock

Tonix Pharmaceuticals Holding Corp.’s Phase II PREVAIL study of TNX-102 SL in long COVID missed its primary endpoint of pain, but it showed a positive signal on the key secondary endpoint – and much more common long COVID symptom – of fatigue, which the company is hoping can take the drug forward into Phase III development. Moreover, the company hopes the fatigue endpoint it plans to use in Phase III could lay the groundwork for future long COVID trials as well.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

17 Feb 2025

• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

20 Jan 2025

• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

13 Nov 2024

• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

17 Oct 2024

• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.